Skip to content

Miromatrix Medical Inc.: 10-Q filed 2023-08-14

What Miromatrix Medical Inc. reported in its quarterly report filed 2023-08-14 (fiscal Q2 2023): 38 published measures, 107 facts as tagged in accession 0001558370-23-014834.

This filing

Form
10-Q (quarterly report)
Filed
2023-08-14
Fiscal period
fiscal Q2 2023
Accession
0001558370-23-014834 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All Miromatrix Medical Inc. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2023-06-3028,451,167USD
At 2022-12-3134,762,930USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2023-06-306,902,917USD
At 2022-12-318,655,526USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2023-06-3021,548,250USD
At 2023-03-3127,800,019USD
At 2022-12-3126,107,404USD
At 2022-06-3040,011,298USD
At 2022-03-3147,457,289USD
At 2021-12-3154,125,884USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2023-06-304,571,777USD
At 2022-12-315,208,005USD
At 2022-06-3012,593,315USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2023-04-01 to 2023-06-30-6,530,420USD91
2023-01-01 to 2023-06-30-14,010,572USD181
2022-04-01 to 2022-06-30-8,182,189USD91
2022-01-01 to 2022-06-30-15,385,938USD181

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2023-01-01 to 2023-06-30-13,684,036USD181
2022-01-01 to 2022-06-30-13,790,978USD181

Contract revenue excluding tax

Revenue from customer contracts excluding assessed taxes under this specific taxonomy concept. It is not automatically comparable to older revenue tags.

PeriodValueUnitDays
2023-04-01 to 2023-06-308,517USD91
2023-01-01 to 2023-06-3016,498USD181
2022-04-01 to 2022-06-303,952USD91
2022-01-01 to 2022-06-3010,720USD181

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2023-01-01 to 2023-06-308,823,077USD181
2022-01-01 to 2022-06-30330,503USD181

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

PeriodValueUnitDays
2023-01-01 to 2023-06-304,224,731USD181
2022-01-01 to 2022-06-30-26,757,741USD181

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2023-06-30-118,022,483USD
At 2022-12-31-104,011,911USD

Basic weighted-average shares

Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.

PeriodValueUnitDays
2023-04-01 to 2023-06-3027,250,573shares91
2023-01-01 to 2023-06-3024,897,796shares181
2022-04-01 to 2022-06-3020,615,218shares91
2022-01-01 to 2022-06-3020,547,070shares181

Diluted weighted-average shares

Weighted-average shares used for diluted earnings per share. Potential shares are included under the applicable dilution rules, not simply added to outstanding shares.

PeriodValueUnitDays
2023-04-01 to 2023-06-3027,250,573shares91
2023-01-01 to 2023-06-3024,897,796shares181
2022-04-01 to 2022-06-3020,615,218shares91
2022-01-01 to 2022-06-3020,547,070shares181

Basic earnings per share

Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.

PeriodValueUnitDays
2023-04-01 to 2023-06-30-0.24USD/shares91
2023-01-01 to 2023-06-30-0.56USD/shares181
2022-04-01 to 2022-06-30-0.4USD/shares91
2022-01-01 to 2022-06-30-0.75USD/shares181

Diluted earnings per share

Reported earnings or loss per share under dilution rules. Antidilutive instruments may be excluded. A diluted value can equal the basic value without implying no potential dilution.

PeriodValueUnitDays
2023-04-01 to 2023-06-30-0.24USD/shares91
2023-01-01 to 2023-06-30-0.56USD/shares181
2022-04-01 to 2022-06-30-0.4USD/shares91
2022-01-01 to 2022-06-30-0.75USD/shares181

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

PeriodValueUnitDays
At 2023-06-304,998,862USD
At 2022-12-315,545,694USD

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

PeriodValueUnitDays
2023-01-01 to 2023-06-30610,610USD181
2022-01-01 to 2022-06-30600,371USD181

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2023-04-01 to 2023-06-30-6,688,412USD91
2023-01-01 to 2023-06-30-14,787,441USD181
2022-04-01 to 2022-06-30-8,234,468USD91
2022-01-01 to 2022-06-30-15,428,096USD181

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2023-06-3021,881,468USD
At 2022-12-3127,310,762USD

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2023-06-303,887,485USD
At 2022-12-314,946,278USD

Current accounts payable

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

PeriodValueUnitDays
At 2023-06-30803,571USD
At 2022-12-311,584,929USD

Net current accounts receivable

Current customer receivables after the allowance for credit loss. The balance is not cash collected or a guarantee of collection.

PeriodValueUnitDays
At 2023-06-308,517USD
At 2022-12-31930,355USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

PeriodValueUnitDays
2023-04-01 to 2023-06-306,571,929USD91
2023-01-01 to 2023-06-3014,553,939USD181
2022-04-01 to 2022-06-308,113,420USD91
2022-01-01 to 2022-06-3015,188,816USD181

Gross profit

Revenue less the costs directly attributed to the goods or services sold. It precedes other operating expenses and is not net income.

PeriodValueUnitDays
2023-04-01 to 2023-06-30-116,483USD91
2023-01-01 to 2023-06-30-233,502USD181
2022-04-01 to 2022-06-30-121,048USD91
2022-01-01 to 2022-06-30-239,280USD181

Selling, general and administrative expense

Selling and general administrative costs reported under this concept. It is an expense category, not a substitute for total operating expenses.

PeriodValueUnitDays
2023-04-01 to 2023-06-302,037,682USD91
2023-01-01 to 2023-06-304,637,917USD181
2022-04-01 to 2022-06-302,188,460USD91
2022-01-01 to 2022-06-304,461,017USD181

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2023-04-01 to 2023-06-303,621,224USD91
2023-01-01 to 2023-06-308,013,342USD181
2022-04-01 to 2022-06-304,988,233USD91
2022-01-01 to 2022-06-308,994,899USD181

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2023-06-3027,310,553shares
At 2022-12-3120,944,109shares

Cash including restricted cash

Cash, cash equivalents and restricted cash as reported in the cash flow reconciliation. Restricted amounts are not freely available, so this is not the same as unrestricted cash.

PeriodValueUnitDays
At 2023-06-305,371,877USD
At 2022-12-316,008,105USD
At 2022-06-3013,393,415USD
At 2021-12-3153,611,631USD

Operating lease right-of-use asset

Carrying amount of the right to use leased assets under operating leases. It reflects discounted remaining payments, not the value of the underlying property.

PeriodValueUnitDays
At 2023-06-301,570,837USD
At 2022-12-311,673,575USD

Operating lease liability

Present value of remaining operating lease payments. Discount-rate choices and lease terms affect the amount; it is not the sum of undiscounted future rent.

PeriodValueUnitDays
At 2023-06-302,917,628USD

Long-term debt

Long-term borrowings under this concept, which can include the current portion depending on presentation. It is not total liabilities and may exclude leases and other obligations.

PeriodValueUnitDays
At 2023-06-30385,997USD

Gross property, plant and equipment

Cost of property, plant and equipment before accumulated depreciation. Historical cost does not indicate current value or replacement cost.

PeriodValueUnitDays
At 2023-06-307,425,085USD
At 2022-12-317,392,550USD

Accumulated depreciation on property, plant and equipment

Cumulative depreciation, depletion and amortization recorded against property, plant and equipment. It measures cost allocation to date, not physical wear or market value.

PeriodValueUnitDays
At 2023-06-302,426,223USD
At 2022-12-311,846,856USD

Accrued current liabilities

Current obligations accrued for goods and services received but not yet invoiced or paid. This is one component of current liabilities, not all short-term obligations.

PeriodValueUnitDays
At 2023-06-301,916,104USD
At 2022-12-311,948,376USD

Prepaid expenses and other current assets

Prepayments and other current assets grouped under this concept. The balance is not cash and its composition differs by filer.

PeriodValueUnitDays
At 2023-06-30114,943USD
At 2022-12-31274,952USD

Profit or loss including noncontrolling interests

Net income or loss including the portion attributable to noncontrolling interests. It can differ from the net income attributable to the parent that per-share figures use.

PeriodValueUnitDays
2023-01-01 to 2023-06-30-14,010,572USD181
2022-01-01 to 2022-06-30-15,385,938USD181

Depreciation, depletion and amortization

Combined depreciation, depletion and amortization for the period. A noncash allocation of asset cost, not a measure of maintenance spending.

PeriodValueUnitDays
2023-04-01 to 2023-06-30289,439USD91
2023-01-01 to 2023-06-30579,367USD181
2022-04-01 to 2022-06-30273,610USD91
2022-01-01 to 2022-06-30536,507USD181

Nonoperating income or expense

Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.

PeriodValueUnitDays
2023-04-01 to 2023-06-30157,992USD91
2023-01-01 to 2023-06-30776,869USD181
2022-04-01 to 2022-06-3052,279USD91
2022-01-01 to 2022-06-3042,158USD181

Interest paid, net

Cash interest paid during the period, net of amounts capitalized where the filer reports it that way. It differs from interest expense recognized.

PeriodValueUnitDays
2023-01-01 to 2023-06-304,052USD181
2022-01-01 to 2022-06-306,066USD181

Inspect the source

Entity
Miromatrix Medical Inc. / CIK 0001527096
Captured
SEC response SHA-256
ac1c579849fd01b61b2056c4353c5bde7d0d5973a346bb0b9cad47792858d02b

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001527096.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))